Biomarkers · Cardiometabolic
Asymmetric Dimethylarginine (ADMA)
Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
ADMA and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in ADMA, study by study
3 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| exercise | Supervised core stabilization exercises delivered by telerehabilitation for 12 weeks in adults with hypertension | ADMA fell from 848.6 to 807.1 (assay units not stated) after 12 weeks of training (p=0.010); unchanged in controls (825.2 to 817.4; p=0.718) | RCT | Duyuler S, Saribas H, Capanoglu MSO, et al. Effect of core stabilization… |
| pharmacologic | Rosuvastatin 10 mg daily for 48 weeks in HIV-positive adults on stable antiretroviral therapy | ADMA changed +0.70% at 48 weeks on rosuvastatin versus +23.78% on placebo (p=0.06) | RCT | Dirajlal-Fargo S, El Kamari V, Sattar A, et al. Effect of statin on arginine… |
| pharmacologic | Paricalcitol 2 micrograms daily for 12 weeks in patients with stage 3-4 CKD | ADMA 0.75 -> 0.72 umol/L at 12 weeks with paricalcitol (placebo 0.75 -> 0.70 umol/L); no treatment effect | RCT | Torino C, Pizzini P, Cutrupi S, et al. Vitamin D and methylarginines in chronic… |
What else moves this marker
They describe those study groups, not an individual, and an association is not a cause.
Diseases and conditions
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ Obstructive sleep apnea · Blood ADMA in OSA patients vs controls | SMD +0.32 (95% CI 0.16 to 0.47) | OSA patients vs controls · OSA patients vs controls (52 studies across 12 oxidative-stress markers) | meta analysis · PMID 34981298 |
| ↑ Rheumatic diseases (pooled) · Circulating ADMA in patients with rheumatic diseases vs healthy controls | SMD +1.27 (95% CI 0.94 to 1.6) | Rheumatic disease patients vs healthy controls · 37 studies; 1,860 rheumatic disease patients and 1,122 healthy controls | meta analysis · PMID 30932011 |
| ↑ Rheumatoid arthritis · Serum/plasma ADMA in RA patients vs healthy controls | SMD +1.02 (95% CI 0.49 to 1.55) | RA patients vs healthy controls · RA patients vs healthy controls, 14 case-control studies | meta analysis · PMID 31376089 |
| ↑ Schizophrenia · Circulating ADMA in schizophrenia vs healthy controls | SMD +1.23 (95% CI 0.86 to 1.61) | Schizophrenia patients vs healthy controls · 21 studies of patients with schizophrenia vs healthy controls | meta analysis · PMID 39414767 |
| ↑ Systemic sclerosis · Blood ADMA in systemic sclerosis vs controls | SMD +0.51 (95% CI 0.12 to 0.91) | SSc patients vs controls · Systemic sclerosis patients vs controls (47 studies across 12 oxidative-stress markers) | meta analysis · PMID 27425641 |
Genetic predisposition
| What | Effect on the marker | Comparison · population | Source |
|---|---|---|---|
| ↑ DDAH1 rs1498373 (CT+TT vs CC) · Plasma ADMA by DDAH1 rs1498373 genotype in hemodialysis patients | +0.05 umol/L | CT+TT 0.87 +/- 0.23 vs CC 0.82 +/- 0.20 uM; difference by subtraction (p=0.02) · 473 hemodialysis patients referred for vascular-access angioplasty (Taiwan) | prospective cohort · PMID 31639806 |
| ↑ DDAH1 rs233112 (GA+GG vs AA) · Plasma ADMA by DDAH1 rs233112 genotype in hemodialysis patients | +0.04 umol/L | GA+GG 0.86 +/- 0.23 vs AA 0.82 +/- 0.19 uM; difference by subtraction (p=0.03) · 473 hemodialysis patients referred for vascular-access angioplasty (Taiwan) | prospective cohort · PMID 31639806 |
Sources
- Risk curve: Schlesinger 2016 (PMID 27812151): all-cause RR 1.52 (1.37-1.68) top vs bottom tertile of circulating ADMA. Scaled to published population values.
- Schlesinger et al. Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies. PloS one. 2016;11:e0165811.
Map Asymmetric Dimethylarginine (ADMA) against another biomarker.
Related markers: Apolipoprotein B to A1 Ratio (ApoB/ApoA1) · Homoarginine · Lipid Accumulation Product (LAP) · Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) · Metabolic Syndrome (Harmonized Definition) · Non-HDL Cholesterol · Trimethylamine N-oxide (TMAO)